• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Tempest Therapeutics Inc.

    6/22/26 8:13:20 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TPST alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox not checkedNoneEntity Type
    0001544227
    Millendo Therapeutics, Inc.
    OvaScience, Inc.
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     Tempest Therapeutics, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     Tempest Therapeutics, Inc.
    Street Address 1Street Address 2
     2000 SIERRA POINT PARKWAY, SUITE 400
     
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     BRISBANE
     CALIFORNIA
     
     94005
     415-798-8589 




    3. Related Persons

    Last NameFirst NameMiddle Name
    Angel
    Matthew
    Street Address 1Street Address 2
     Tempest Therapeutics, Inc. 
     2000 Sierra Point Parkway, Suite 400
    CityState/Province/CountryZIP/Postal Code
     Brisbane
     CALIFORNIA
     94005
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    President and Chief Executive Officer



    Last NameFirst NameMiddle Name
    Trojanowski
    Justin
    Street Address 1Street Address 2
     Tempest Therapeutics, Inc. 
     2000 Sierra Point Parkway, Suite 400
    CityState/Province/CountryZIP/Postal Code
     Brisbane
     CALIFORNIA
     94005
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Vice President, Finance, Principal Financial Officer and Corporate Secretary



    Last NameFirst NameMiddle Name
    Yee
    John
    David
    Street Address 1Street Address 2
     Tempest Therapeutics, Inc. 
     2000 Sierra Point Parkway, Suite 400
    CityState/Province/CountryZIP/Postal Code
     Brisbane
     CALIFORNIA
     94005
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Richey
    William
    Drake
    Street Address 1Street Address 2
     Tempest Therapeutics, Inc. 
     2000 Sierra Point Parkway, Suite 400
    CityState/Province/CountryZIP/Postal Code
     Brisbane
     CALIFORNIA
     94005
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button not checked Pharmaceuticals
     Radio button not checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button not checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-05-29
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button checked Yes Radio button not checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox checkedOther (describe)
    Common Stock Purchase Warrant, including underlying shares of common stock
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button checked Yes Radio button not checked No
    Clarification of Response (if Necessary)
     
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     
     
    (Associated) Broker or DealerCheckbox not checkedNone(Associated) Broker or Dealer CRD Number  Checkbox not checkedNone
     
     
    Street Address 1Street Address 2
     
     
    City State/Province/CountryZIP/Postal Code
     
     
     
    State(s) of Solicitation Checkbox not checkedAll States
     



    13. Offering and Sales Amounts
     
    Total Offering Amount $
    4056552
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    4056552
    USD
    Total Remaining to be Sold $
    0
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
    Offering amount for common stock purchase warrant does not include proceeds of $2028276 for warrant exercise. (amounts rounded)
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    0
    USDCheckbox not checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    Tempest Therapeutics, Inc./s/ Matthew AngelMatthew AngelPresident and Chief Executive Officer2026-06-22




    Get the next $TPST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TPST

    DatePrice TargetRatingAnalyst
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    4/10/2025Sector Outperform → Sector Perform
    Scotiabank
    4/10/2025Buy → Neutral
    H.C. Wainwright
    3/14/2024$13.00Sector Outperform
    Scotiabank
    2/8/2024$15.00Buy
    Jefferies
    10/21/2021Outperform
    William Blair
    7/13/2021$51.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $TPST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Angel Matthew bought $500,001 worth of shares (231,482 units at $2.16) (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    6/23/26 4:56:17 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Brady Stephen R bought $73,850 worth of shares (35,000 units at $2.11), increasing direct ownership by 308% to 46,376 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/8/24 4:15:11 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Whiting Samuel bought $9,951 worth of shares (4,672 units at $2.13), increasing direct ownership by 95% to 9,573 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/3/24 7:35:42 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    SEC Filings

    View All

    SEC Form 8-K filed by Tempest Therapeutics Inc.

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    6/22/26 8:22:28 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Tempest Therapeutics Inc.

    D - Tempest Therapeutics, Inc. (0001544227) (Filer)

    6/22/26 8:13:20 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Tempest Therapeutics Inc.

    DEF 14A - Tempest Therapeutics, Inc. (0001544227) (Filer)

    6/8/26 4:06:34 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tempest Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Tempest Therapeutics from Neutral to Buy and set a new price target of $11.00

    1/22/26 8:24:05 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics downgraded by Scotiabank

    Scotiabank downgraded Tempest Therapeutics from Sector Outperform to Sector Perform

    4/10/25 8:50:49 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Tempest Therapeutics from Buy to Neutral

    4/10/25 8:03:29 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Angel Matthew bought $500,001 worth of shares (231,482 units at $2.16) (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    6/23/26 4:56:17 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Yee John D.

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    6/17/26 7:24:54 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Yee John D.

    3 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    6/17/26 7:19:48 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

    BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest" or "Tempest Therapeutics") today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the "Board"), effective [June 4, 2026]. Mr. Richey and Dr. Yee collectively bring decades of experience in corporate finance and therapeutic product development to the Board. "Over the past several months, we have built a portfolio of CAR-T cell therapy product candidates targeting safe, effective treatments for patients with advanced cancers," said Matt Angel, Ph.D., President and CEO of Tempest. "The addition of Drake and John to the Boa

    6/4/26 4:37:05 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

    BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) (the "Company"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the entry a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 1,172,414 shares of the Company's common stock originally issued by the Company on November 26, 2025, having an original exercise price of $3.50 per share, at a reduced exercise price of $1.73 per share. The closing of the warrant exercise transaction is expected to occur on or about May 29, 2025, subject to satisfaction of

    5/29/26 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

    Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children's Applied Gene and Cell Therapy Center ("AGCTC") as Lead Manufacturing Partner Appointed Andrew Fang, Ph.D., as Head of Business Development BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. "We made strong progress in the first

    5/14/26 4:15:00 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Leadership Updates

    Live Leadership Updates

    View All

    Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

    BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest" or "Tempest Therapeutics") today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the "Board"), effective [June 4, 2026]. Mr. Richey and Dr. Yee collectively bring decades of experience in corporate finance and therapeutic product development to the Board. "Over the past several months, we have built a portfolio of CAR-T cell therapy product candidates targeting safe, effective treatments for patients with advanced cancers," said Matt Angel, Ph.D., President and CEO of Tempest. "The addition of Drake and John to the Boa

    6/4/26 4:37:05 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

    Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children's Applied Gene and Cell Therapy Center ("AGCTC") as Lead Manufacturing Partner Appointed Andrew Fang, Ph.D., as Head of Business Development BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. "We made strong progress in the first

    5/14/26 4:15:00 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

    Adds dedicated business development leadership to support Tempest's strategic prioritiesWill lead China outreach and cross-border partnership effortsTo support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities BRISBANE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the appointment of Andrew Fang, Ph.D., as Head of Business Development. Dr. Fang will lead Tempest's global business development efforts, including strategic partners

    4/14/26 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Financials

    Live finance-specific insights

    View All

    Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

    BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the "Record Date") for the distribution of warrants to purchase Tempest common stock ("Warrants") as a dividend (the "Warrant Dividends"), as contemplated by Tempest's previously announced Asset Purchase Agreement (the "Asset Purchase Agreement") with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of c

    1/20/26 5:20:02 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Extends Limited Duration Stockholder Rights Plan

    BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest" or the "Company"), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that its Board of Directors (the "Board") has adopted an amendment to its existing limited duration stockholder rights plan (as amended, the "Rights Plan") to extend the duration of the Rights Plan until the Annual Meeting of Stockholders. "Given the significant milestones reached this year in the amezalpat program – the positive survival data compared to standard of care and broad agreement with FDA on the Phase 3 path – coupled

    10/10/24 7:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

    21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier Early and persistent separation of survival curves OS is the primary regulatory endpoint for first-line HCCCompany to host webcast conference call today at 8:30am ET BRISBANE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced new positive data from the ongoing global randomized Phase 1b/2 clinica

    6/20/24 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Tempest Therapeutics Inc.

    SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    8/12/24 8:59:00 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Tempest Therapeutics Inc. (Amendment)

    SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    5/13/24 4:54:01 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Tempest Therapeutics Inc. (Amendment)

    SC 13G/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    2/14/24 6:49:42 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care